An approved GLP-1 receptor agonist with formulation- and indication-specific evidence for diabetes, weight management and cardiovascular outcomes. This record separates established identity and source-linked research context from protocol or commercial fields that are not yet supportable.
FEMETRIC RECORD · PUBLICSemaglutide
Weight ManagementAppetiteGlucose / Insulin
Status
Approved
Related
4
Sources
1
UPDATED 2026-09-13
01
Protocol references
SOURCE-LINKED
PUBLISHED STUDY
Source-linked research context
No universal administration structure is inferred from the indexed literature. Open the source for the population, intervention and study design.
Route
Subcutaneous · Oral
Frequency
See indexed source
Duration
Not indexed
Escalation
Not established
Stage detail pending source extractionStarting and target doses are indexed. Intermediate steps are intentionally not inferred.
PUBLISHED STUDYNew England Journal of Medicine, 2021Verified 2026-09-13
Semaglutide is a long-acting GLP-1 receptor agonist. Oral and injectable products are not interchangeable, and study results must be read in their formulation and indication context.
Mechanism summaries are stored with field-level source provenance for editorial audit.
07
Related research goals
08
Related peptides
01PEPTIDE
Tirzepatide
An approved dual GIP and GLP-1 receptor agonist studied across type 2 diabetes, obesity and cardiometabolic outcomes.
Weight ManagementAppetiteGlucose / Insulin
02PEPTIDE
Retatrutide
An investigational GIP, GLP-1 and glucagon receptor agonist studied for obesity and metabolic outcomes.
Weight ManagementAppetiteGlucose / Insulin
03PEPTIDE
Liraglutide
An approved daily GLP-1 receptor agonist studied for type 2 diabetes, weight management and cardiovascular outcomes.
Weight ManagementAppetiteGlucose / Insulin
04PEPTIDE
CagriSema
An investigational fixed combination of cagrilintide and semaglutide studied in metabolic and weight-management trials.